ARTICLE | Company News
MOGN gets rights to palonosetron
February 13, 2001 8:00 AM UTC
MGI Pharma entered into a letter of intent with Helsinn Healthcare granting MOGN exclusive North American distribution rights to palonosetron, an intravenous 5-HT3 serotonin receptor antagonist with a...